BetterLife Pharma (TSE:BETR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BetterLife Pharma Inc. has successfully completed a non-brokered private placement, raising $175,000 through the issuance of 1.75 million units at $0.10 each, which includes common shares and full warrants exercisable within 24 months. The company is advancing in the biotech field with a focus on neuro-psychiatric and neurological treatments, including two lead compounds, BETR-001 and BETR-002, which are in preclinical stages targeting mental disorders and anxiety-related conditions.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.